Inipharm
6 employees on LinkedIn · 2 known investors
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
Founders & leadership
CC
Chuhan ChungChief Medical Officer
Investors · 2
Competitors · 2
by search overlap
IQVIA103 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld65 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Inipharm for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Inipharm do?
- Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
- Who are Inipharm's investors?
- Inipharm's investors include 5AM Ventures, Frazier Life Sciences.